Predictive Vulnerability Intelligence.

Product

  • Product
  • Pricing
  • Documentation

Company

  • About
  • Partnerships
  • Blog
  • Support

Legal

  • Terms
  • Privacy
  • Data Licensing

© 2026 FAUCET Technologies LLC. All rights reserved.

CVE-2017-18228

19
FAUCET Score

CVE-2017-18228 describes a Cross-Site Scripting (XSS) vulnerability in the Remedy Mid Tier component of BMC Remedy AR System version 9.1. An attacker can exploit this by injecting malicious script into the ATTKey parameter within an arsys/servlet/AttachServlet request. Rated Medium with a CVSS score of 5.4, this vulnerability requires user interaction and low privileges, potentially leading to limited impact on confidentiality and integrity. There is no evidence of active exploitation, publicly available exploit code, or significant community discussion or media coverage for this CVE.

Impacted Technologies

VendorProductVersion(s)CPE
<= 9.1CPE matchmatch criteria
cpe:2.3:a:bmc:remedy_action_request_system:*:*:*:*:*:*:*:*

CVSS Data

CVSS version used by this source: 3.0

5.4MEDIUM

CVSS:3.0/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N

Attack Vector
NETWORK
Attack Complexity
LOW
Privileges Required
LOW
User Interaction
REQUIRED
Scope
CHANGED
Confidentiality Impact
LOW
Integrity Impact
LOW
Availability Impact
NONE
Exploitability Score
2.3
Impact Score
2.7
CvssVersion
3.0

Exploit Intelligence

EPSS Score
0.52%
Probability of exploitation in next 30 days
EPSS Percentile
41.2%
Percentile rank of EPSS score among Peer Group
As of 2026-07-28
Model: v2026.06.15
This CVE's current EPSS score of 0.0052 is in the 64th percentile among its peer group of 15,239 CVEs.

Social Chatter

The average CVE in this peer group has 0.0 Twitter, 0.0 Reddit, 0.0 Bluesky, 0.0 Mastodon, and 0.1 GitHub mentions.

Media Mentions

No media coverage found for this CVE.

The average CVE in this peer group has 0.0 InfoSec Media, 0.0 Vendor Blog, and 0.0 Security Researcher mentions.

Remediation

Remediation records are not available for this CVE.

References

communities.bmc.com / thread/164169
Vendor Advisory